VEGF-A, a protein with potent proangiogenic activity, may enhance immune system suppression in the tumor microenvironment (TME), as previously reported; more specifically, VEGF-A produced by tumor cells may enhance the expression of PD-1 and other inhibitory checkpoint molecules involved in the inactivation of CD8+ T cells [21]. The gene discussed is PDCD1; the disease is neoplasm.